Dentsply Sirona Inc Financials
Dentsply Sirona Inc (XRAY) reported $3.7B in revenue for fiscal year 2025, down 3.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Positive operating cash flow is masking a thinner equity cushion as margin erosion and payouts outlast sales pressure.
Over the last three fiscal years, accounting losses and cash generation diverged: net loss reached-$598M while operating cash flow stayed positive at$235M . That gap points to heavy non-cash charges, but with free cash flow below dividends in FY2025, the balance sheet rather than the business is now supporting cash returns.
In the latest year, the operating loss narrowed even as revenue slipped to
The capital structure has tightened materially: debt to equity rose to 1.5x as total equity fell to
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Dentsply Sirona Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Dentsply Sirona Inc has an operating margin of -11.5%, meaning the company loses $11 on every $100 of revenue. This results in a profitability score of 22/100. This is up from -23.2% the prior year.
Dentsply Sirona Inc's revenue declined 3.0% year-over-year, from $3.8B to $3.7B. This contraction results in a growth score of 20/100.
Dentsply Sirona Inc has a moderate D/E ratio of 1.50. This balance of debt and equity financing earns a leverage score of 36/100.
Dentsply Sirona Inc's current ratio of 1.51 indicates adequate short-term liquidity, earning a score of 41/100. The company can meet its near-term obligations, though with limited headroom.
Dentsply Sirona Inc has a free cash flow margin of 2.8%, earning a moderate score of 47/100. The company generates positive cash flow after capital investments, but with room for improvement.
Dentsply Sirona Inc posts a -44.7% return on equity (ROE), meaning it loses $45 for every $100 of shareholders' equity. This results in a returns score of 22/100. This is up from -46.9% the prior year.
Dentsply Sirona Inc scores 0.48, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($2.1B) relative to total liabilities ($4.1B). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Dentsply Sirona Inc passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Dentsply Sirona Inc reported a net loss of $598.0M while generating $235.0M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Dentsply Sirona Inc reported an operating loss of $422.0M against $88.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Dentsply Sirona Inc generated $3.7B in revenue in fiscal year 2025. This represents a decrease of 3.0% from the prior year.
Dentsply Sirona Inc's EBITDA was -$70.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 86.8% from the prior year.
Dentsply Sirona Inc reported -$598.0M in net income in fiscal year 2025. This represents an increase of 34.3% from the prior year.
Dentsply Sirona Inc earned -$3.00 per diluted share (EPS) in fiscal year 2025. This represents an increase of 33.0% from the prior year.
Cash & Balance Sheet
Dentsply Sirona Inc generated $104.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 63.0% from the prior year.
Dentsply Sirona Inc held $326.0M in cash against $2.0B in long-term debt as of fiscal year 2025.
Dentsply Sirona Inc paid $0.64 per share in dividends in fiscal year 2025. That is unchanged from the prior year.
Margins & Returns
Dentsply Sirona Inc's gross margin was 50.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.6 percentage points from the prior year.
Dentsply Sirona Inc's operating margin was -11.5% in fiscal year 2025, reflecting core business profitability. This is up 11.7 percentage points from the prior year.
Dentsply Sirona Inc's net profit margin was -16.3% in fiscal year 2025, showing the share of revenue converted to profit. This is up 7.7 percentage points from the prior year.
Dentsply Sirona Inc's ROE was -44.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 2.2 percentage points from the prior year.
Capital Allocation
Dentsply Sirona Inc invested $150.0M in research and development in fiscal year 2025. This represents a decrease of 9.1% from the prior year.
Dentsply Sirona Inc repurchased no shares in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
Dentsply Sirona Inc invested $131.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 27.2% from the prior year.
XRAY Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.6B | $3.7B-3.0% | $3.8B-4.3% | $4.0B+1.1% | $3.9B-7.3% | $4.2B+26.7% | $3.3B-17.0% | $4.0B+0.9% | $4.0B-0.2% | $4.0B+6.6% | $3.7B+40.0% | $2.7B-8.5% | $2.9B-1.0% | $3.0B+0.8% | $2.9B+15.4% | $2.5B |
| Cost of Revenue | $1.8B | $1.8B+0.3% | $1.8B-2.3% | $1.9B+4.7% | $1.8B-4.7% | $1.9B+11.9% | $1.7B-9.4% | $1.9B-3.1% | $1.9B+6.3% | $1.8B+3.5% | $1.7B+50.8% | $1.2B-12.5% | $1.3B-3.7% | $1.4B+0.1% | $1.4B+8.5% | $1.3B |
| Gross Profit | $1.8B | $1.8B-6.0% | $2.0B-6.1% | $2.1B-1.9% | $2.1B-9.4% | $2.3B+41.7% | $1.7B-23.5% | $2.2B+4.6% | $2.1B-5.5% | $2.2B+9.4% | $2.0B+31.9% | $1.5B-5.2% | $1.6B+1.4% | $1.6B+1.4% | $1.6B+22.2% | $1.3B |
| R&D Expenses | $166.0M | $150.0M-9.1% | $165.0M-10.3% | $184.0M+5.7% | $174.0M+1.8% | $171.0M+39.0% | $123.0M-14.0% | $143.0M-11.2% | $161.0M+6.1% | $151.7M+18.1% | $128.5M+71.6% | $74.9M-7.3% | $80.8M-5.1% | $85.1M-0.4% | $85.4M0.0% | $85.4M |
| SG&A Expenses | $1.5B | $1.4B-10.4% | $1.6B-0.5% | $1.6B+1.5% | $1.6B+2.5% | $1.6B+19.1% | $1.3B-18.0% | $1.6B-7.7% | $1.7B+2.6% | $1.7B+10.0% | $1.5B+41.4% | $1.1B-5.8% | $1.1B-0.1% | $1.1B-0.3% | $1.1B+22.6% | $936.8M |
| Operating Income | -$310.0M | -$422.0M+52.0% | -$879.0M-934.1% | -$85.0M+90.9% | -$937.0M-254.1% | $608.0M+20366.7% | -$3.0M-100.8% | $353.0M+136.8% | -$958.0M+38.7% | -$1.6B-443.6% | $454.7M+21.2% | $375.2M-15.8% | $445.6M+6.3% | $419.2M+9.8% | $381.9M+27.0% | $300.7M |
| Interest Expense | $91.0M | $88.0M+27.5% | $69.0M-14.8% | $81.0M+24.6% | $65.0M+6.6% | $61.0M+27.1% | $48.0M+60.0% | $30.0M-18.9% | $37.0M-3.4% | $38.3M+6.7% | $35.9M-35.8% | $55.9M+19.2% | $46.9M-5.4% | $49.6M-12.8% | $56.9M+29.8% | $43.8M |
| Income Tax | $200.0M | $112.0M+530.8% | -$26.0M+39.5% | -$43.0M+59.0% | -$105.0M-178.4% | $134.0M+482.6% | $23.0M-72.0% | $82.0M+54.7% | $53.0M+199.6% | -$53.2M-660.0% | $9.5M-87.7% | $77.0M-5.1% | $81.1M+55.4% | $52.2M+485.2% | $8.9M-19.0% | $11.0M |
| Net Income | -$546.0M | -$598.0M+34.3% | -$910.0M-589.4% | -$132.0M+86.1% | -$950.0M-331.1% | $411.0M+663.0% | -$73.0M-128.5% | $256.0M+125.3% | -$1.0B+34.8% | -$1.6B-460.5% | $429.9M+71.1% | $251.2M-22.2% | $322.9M+3.1% | $313.2M-0.3% | $314.2M+28.5% | $244.5M |
| EPS (Diluted) | — | -$3.00+33.0% | -$4.48-622.6% | -$0.62+85.9% | -$4.41-335.8% | $1.87+666.7% | -$0.33-128.9% | $1.14+125.3% | -$4.51+33.3% | -$6.76-448.5% | $1.94 | $1.76-21.4% | $2.24+3.7% | $2.16-0.9% | $2.18+28.2% | $1.70 |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
XRAY Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $5.4B-5.6% | $5.8B-21.9% | $7.4B-3.6% | $7.6B-17.3% | $9.2B-1.2% | $9.3B+8.7% | $8.6B-1.0% | $8.7B-16.3% | $10.4B-10.2% | $11.6B+162.5% | $4.4B-5.2% | $4.6B-8.4% | $5.1B+2.0% | $5.0B+4.6% | $4.8B |
| Current Assets | $2.0B+15.9% | $1.7B-11.5% | $2.0B+4.2% | $1.9B+2.2% | $1.9B+3.0% | $1.8B-10.1% | $2.0B+5.9% | $1.9B-5.7% | $2.0B+14.9% | $1.7B+45.7% | $1.2B-0.9% | $1.2B+5.5% | $1.1B+2.9% | $1.1B+9.7% | $1.0B |
| Cash & Equivalents | $326.0M+19.9% | $272.0M-18.6% | $334.0M-8.5% | $365.0M+7.7% | $339.0M-22.6% | $438.0M+8.1% | $405.0M+30.8% | $309.6M-3.4% | $320.6M-16.5% | $383.9M+34.9% | $284.6M+87.7% | $151.6M+102.1% | $75.0M-6.4% | $80.1M+3.9% | $77.1M |
| Inventory | $642.0M+13.8% | $564.0M-9.6% | $624.0M-0.5% | $627.0M+21.7% | $515.0M+8.2% | $476.0M-15.3% | $562.0M-6.2% | $598.9M-3.9% | $623.1M+20.5% | $517.1M+51.9% | $340.4M-12.1% | $387.1M-11.7% | $438.6M+8.8% | $402.9M+11.4% | $361.8M |
| Goodwill | $1.1B-28.1% | $1.6B-34.5% | $2.4B-9.3% | $2.7B-32.4% | $4.0B-0.3% | $4.0B+17.3% | $3.4B-1.0% | $3.4B-24.4% | $4.5B-23.7% | $6.0B+199.5% | $2.0B-4.9% | $2.1B-8.4% | $2.3B+3.2% | $2.2B+1.0% | $2.2B |
| Total Liabilities | $4.1B+7.3% | $3.8B-6.5% | $4.1B+6.4% | $3.8B-9.7% | $4.2B-3.9% | $4.4B+25.9% | $3.5B-1.3% | $3.6B-5.1% | $3.7B+9.2% | $3.4B+66.2% | $2.1B-11.2% | $2.3B-6.9% | $2.5B-8.3% | $2.7B-5.2% | $2.9B |
| Current Liabilities | $1.3B-15.5% | $1.6B+11.5% | $1.4B+21.8% | $1.2B-7.2% | $1.3B-8.1% | $1.4B+37.9% | $995.0M-1.8% | $1.0B+6.2% | $954.5M+24.3% | $767.6M+61.3% | $476.0M-27.1% | $652.6M-17.8% | $793.8M-14.4% | $927.8M+28.1% | $724.1M |
| Long-Term Debt | $2.0B+27.0% | $1.6B-11.7% | $1.8B-1.6% | $1.8B-4.5% | $1.9B-3.3% | $2.0B+38.0% | $1.4B-8.4% | $1.6B-2.9% | $1.6B+6.7% | $1.5B+32.4% | $1.1B-0.8% | $1.2B-1.2% | $1.2B-4.7% | $1.2B-18.0% | $1.5B |
| Total Equity | $1.3B-31.1% | $1.9B-41.0% | $3.3B-13.6% | $3.8B-23.7% | $5.0B+1.3% | $4.9B-3.2% | $5.1B-0.5% | $5.1B-22.6% | $6.6B-18.5% | $8.1B+247.1% | $2.3B+0.7% | $2.3B-8.4% | $2.5B+14.8% | $2.2B+19.5% | $1.8B |
| Retained Earnings | -$1.6B-87.3% | -$835.0M-507.3% | $205.0M-55.0% | $456.0M-69.9% | $1.5B+26.4% | $1.2B-14.7% | $1.4B+14.5% | $1.2B-47.1% | $2.3B-41.3% | $3.9B+9.9% | $3.6B+6.2% | $3.4B+9.2% | $3.1B+9.8% | $2.8B+11.2% | $2.5B |
Not reported in any period shown, so not listed: Accounts Receivable.
XRAY Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $319.0M | $235.0M-49.0% | $461.0M+22.3% | $377.0M-27.1% | $517.0M-21.3% | $657.0M+1.2% | $649.0M+1.6% | $639.0M+27.8% | $500.0M-16.9% | $601.9M+6.8% | $563.4M+13.3% | $497.4M-11.2% | $560.4M+34.1% | $417.8M+13.0% | $369.7M-6.0% | $393.5M |
| Capital Expenditures | $176.0M | $131.0M-27.2% | $180.0M+20.8% | $149.0M0.0% | $149.0M+4.9% | $142.0M+63.2% | $87.0M-29.3% | $123.0M-32.8% | $183.0M+26.8% | $144.3M+15.4% | $125.0M+73.6% | $72.0M-27.7% | $99.6M-0.7% | $100.3M+8.9% | $92.1M+29.3% | $71.2M |
| Free Cash Flow | $143.0M | $104.0M-63.0% | $281.0M+23.2% | $228.0M-38.0% | $368.0M-28.5% | $515.0M-8.4% | $562.0M+8.9% | $516.0M+62.8% | $317.0M-30.7% | $457.6M+4.4% | $438.4M+3.1% | $425.4M-7.7% | $460.8M+45.1% | $317.5M+14.4% | $277.6M-13.9% | $322.3M |
| Investing Cash Flow | -$173.0M | -$132.0M+33.0% | -$197.0M-121.3% | -$89.0M+35.5% | -$138.0M+61.5% | -$358.0M+67.6% | -$1.1B-1502.9% | -$69.0M+72.7% | -$253.0M+11.7% | -$286.4M-577.3% | $60.0M+209.3% | -$54.9M+60.4% | -$138.7M+46.7% | -$260.2M-126.2% | -$115.0M+93.9% | -$1.9B |
| Financing Cash Flow | -$265.0M | -$80.0M+73.5% | -$302.0M+1.6% | -$307.0M+6.7% | -$329.0M+13.2% | -$379.0M-179.6% | $476.0M+200.8% | -$472.0M-88.8% | -$250.0M+37.6% | -$400.8M+23.8% | -$526.2M-73.7% | -$302.9M+9.9% | -$336.2M-107.9% | -$161.7M+36.7% | -$255.6M-125.5% | $1.0B |
| Dividends Paid | $96.0M | $128.0M+1.6% | $126.0M+8.6% | $116.0M+11.5% | $104.0M+13.0% | $92.0M+4.5% | $88.0M+8.6% | $81.0M+2.5% | $79.0M+0.9% | $78.3M+21.2% | $64.6M+61.5% | $40.0M+7.2% | $37.3M+7.2% | $34.8M+10.7% | $31.4M+9.8% | $28.6M |
| Share Buybacks | N/A | $0-100.0% | $250.0M-16.7% | $300.0M+100.0% | $150.0M-25.0% | $200.0M+42.9% | $140.0M-46.2% | $260.0M+4.0% | $250.0M-37.7% | $401.4M-50.7% | $813.9M+622.2% | $112.7M-30.9% | $163.2M+38.3% | $118.0M+203.8% | $38.8M-51.1% | $79.5M |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
XRAY Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 50.0%-1.6pp | 51.6%-1.0pp | 52.6%-1.6pp | 54.2%-1.2pp | 55.5%+5.9pp | 49.6%-4.2pp | 53.8%+1.9pp | 51.9%-2.9pp | 54.8%+1.4pp | 53.4%-3.3pp | 56.7%+2.0pp | 54.7%+1.3pp | 53.5%+0.3pp | 53.1%+3.0pp | 50.2% |
| Operating Margin | -11.5%+11.7pp | -23.2%-21.0pp | -2.1%+21.8pp | -23.9%-38.3pp | 14.4%+14.5pp | -0.1%-8.9pp | 8.8%+32.8pp | -24.0%+15.1pp | -39.1%-51.3pp | 12.1%-1.9pp | 14.0%-1.2pp | 15.3%+1.0pp | 14.2%+1.2pp | 13.0%+1.2pp | 11.8% |
| Net Margin | -16.3%+7.7pp | -24.0%-20.7pp | -3.3%+20.9pp | -24.2%-33.9pp | 9.7%+11.9pp | -2.2%-8.6pp | 6.4%+31.7pp | -25.4%+13.5pp | -38.8%-50.3pp | 11.5%+2.1pp | 9.4%-1.7pp | 11.1%+0.4pp | 10.6%-0.1pp | 10.7%+1.1pp | 9.6% |
| Return on Equity | -44.7%+2.2pp | -46.9%-42.9pp | -4.0%+20.9pp | -24.9%-33.2pp | 8.2%+9.7pp | -1.5%-6.5pp | 5.0%+24.8pp | -19.7%+3.7pp | -23.4%-28.7pp | 5.3%-5.4pp | 10.7%-3.2pp | 13.9%+1.6pp | 12.3%-1.9pp | 14.2%+1.0pp | 13.2% |
| Return on Assets | -11.0%+4.8pp | -15.8%-14.0pp | -1.8%+10.6pp | -12.4%-16.9pp | 4.5%+5.2pp | -0.8%-3.8pp | 3.0%+14.6pp | -11.6%+3.3pp | -14.9%-18.7pp | 3.7%-2.0pp | 5.7%-1.2pp | 7.0%+0.8pp | 6.2%-0.2pp | 6.3%+1.2pp | 5.1% |
| Current Ratio | 1.51+0.4x | 1.10-0.3x | 1.38-0.2x | 1.62+0.1x | 1.47+0.2x | 1.31-0.7x | 2.01+0.1x | 1.86-0.2x | 2.10-0.2x | 2.27-0.2x | 2.51+0.7x | 1.85+0.4x | 1.44+0.2x | 1.20-0.2x | 1.40 |
| Debt-to-Equity | 1.50+0.7x | 0.82+0.3x | 0.55+0.1x | 0.48+0.1x | 0.380.0x | 0.40+0.1x | 0.280.0x | 0.31+0.1x | 0.24+0.1x | 0.19-0.3x | 0.490.0x | 0.500.0x | 0.46-0.1x | 0.55-0.3x | 0.81 |
| FCF Margin | 2.8%-4.6pp | 7.4%+1.7pp | 5.8%-3.6pp | 9.4%-2.8pp | 12.2%-4.7pp | 16.8%+4.0pp | 12.8%+4.9pp | 8.0%-3.5pp | 11.5%-0.3pp | 11.7%-4.2pp | 15.9%+0.1pp | 15.8%+5.0pp | 10.8%+1.3pp | 9.5%-3.2pp | 12.7% |
Similar Companies
Where Dentsply Sirona Inc Ranks
Frequently Asked Questions
What is Dentsply Sirona Inc's annual revenue?
Dentsply Sirona Inc (XRAY) reported $3.7B in total revenue for fiscal year 2025. This represents a -3.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Dentsply Sirona Inc's revenue growing?
Dentsply Sirona Inc (XRAY) revenue declined by 3.0% year-over-year, from $3.8B to $3.7B in fiscal year 2025.
Is Dentsply Sirona Inc profitable?
No, Dentsply Sirona Inc (XRAY) reported a net income of -$598.0M in fiscal year 2025, with a net profit margin of -16.3%.
What is Dentsply Sirona Inc's EBITDA?
Dentsply Sirona Inc (XRAY) had EBITDA of -$70.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Dentsply Sirona Inc have?
As of fiscal year 2025, Dentsply Sirona Inc (XRAY) had $326.0M in cash and equivalents against $2.0B in long-term debt.
What is Dentsply Sirona Inc's gross margin?
Dentsply Sirona Inc (XRAY) had a gross margin of 50.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Dentsply Sirona Inc's operating margin?
Dentsply Sirona Inc (XRAY) had an operating margin of -11.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Dentsply Sirona Inc's net profit margin?
Dentsply Sirona Inc (XRAY) had a net profit margin of -16.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Does Dentsply Sirona Inc pay dividends?
Yes, Dentsply Sirona Inc (XRAY) paid $0.64 per share in dividends during fiscal year 2025.
What is Dentsply Sirona Inc's return on equity (ROE)?
Dentsply Sirona Inc (XRAY) has a return on equity of -44.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Dentsply Sirona Inc's free cash flow?
Dentsply Sirona Inc (XRAY) generated $104.0M in free cash flow during fiscal year 2025. This represents a -63.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Dentsply Sirona Inc's operating cash flow?
Dentsply Sirona Inc (XRAY) generated $235.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Dentsply Sirona Inc's total assets?
Dentsply Sirona Inc (XRAY) had $5.4B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Dentsply Sirona Inc's capital expenditures?
Dentsply Sirona Inc (XRAY) invested $131.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Dentsply Sirona Inc spend on research and development?
Dentsply Sirona Inc (XRAY) invested $150.0M in research and development during fiscal year 2025.
What is Dentsply Sirona Inc's current ratio?
Dentsply Sirona Inc (XRAY) had a current ratio of 1.51 as of fiscal year 2025, which is generally considered healthy.
What is Dentsply Sirona Inc's debt-to-equity ratio?
Dentsply Sirona Inc (XRAY) had a debt-to-equity ratio of 1.50 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Dentsply Sirona Inc's return on assets (ROA)?
Dentsply Sirona Inc (XRAY) had a return on assets of -11.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Dentsply Sirona Inc's Altman Z-Score?
Dentsply Sirona Inc (XRAY) has an Altman Z-Score of 0.48, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Dentsply Sirona Inc's Piotroski F-Score?
Dentsply Sirona Inc (XRAY) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Dentsply Sirona Inc's earnings high quality?
Dentsply Sirona Inc (XRAY) reported a net loss of $598.0M while generating $235.0M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Dentsply Sirona Inc cover its interest payments?
Dentsply Sirona Inc (XRAY) reported an operating loss of $422.0M against $88.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Dentsply Sirona Inc?
Dentsply Sirona Inc (XRAY) scores 31 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.